The FDA has approved Novartis‘ Zortress oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. The drug, generically known as everolimus, is marketed as Certican in more than 70 countries as part of the immunosuppressive regimen for transplant patients. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids. Calcineurin inhibit...